Group 1 - The core point of the article is that CSPC Pharmaceutical Group (01093.HK) has received approval from the National Medical Products Administration of China to conduct clinical trials for its self-developed drug SYH2085 [1] - SYH2085 is a novel oral small molecule candidate drug designed to inhibit the RNA polymerase acidic protein (PA) endonuclease activity of the influenza virus, targeting both influenza A and B viruses [1] - The clinical indication approved is for the treatment of uncomplicated influenza in adults and adolescents aged 12 and above, with preclinical studies showing significant antiviral effects and favorable pharmacokinetic properties [1] Group 2 - The approval of SYH2085 is expected to enhance the company's product pipeline in the field of anti-infective treatments, indicating high clinical development value [1] - Additionally, CSPC Pharmaceutical Group announced the appointment of Cai Lei as Vice Chairman and Executive Director [2]
石药集团(01093.HK)：“SYH2085片”在中国获临床试验批准